- Home
- DMLP vs IMTX Comparison
DMLP vs IMTX Comparison
Compare DMLP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$10.64
Company Overview
Basic Information| Metric | DMLP | IMTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Germany |
| Employees | 26 | 407 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | DMLP | IMTX |
|---|---|---|
| Price | $28.73 | $10.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 160.6K | ★ 407.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 9.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $152,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $47.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.85 | $4.93 |
| 52 Week High | $28.95 | $12.41 |
Technical Indicators
Market Signals| Indicator | DMLP | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 45.62 |
| Support Level | $23.97 | $10.57 |
| Resistance Level | $28.77 | $11.54 |
| Average True Range (ATR) | 0.67 | 0.59 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 95.82 | 26.14 |
Price Performance
Historical Comparison DMLP
IMTX
About DMLP Dorchester Minerals L.P.
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.